Novocure Ltd Stock
€13.50
Your prediction
Novocure Ltd Stock
Pros and Cons of Novocure Ltd in the next few years
Pros
Cons
Performance of Novocure Ltd vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Novocure Ltd | 0.780% | 7.378% | -10.971% | -75.204% | -6.200% | -87.619% | - |
Ironwood Pharmaceuticals | 2.600% | -3.049% | -42.391% | -20.785% | -23.558% | -11.667% | -31.701% |
Iovance Biotherapeutics Inc. | 0.810% | -4.442% | -19.187% | 128.293% | 66.688% | -47.104% | - |
Fibrogen Inc. | -2.460% | 3.670% | 16.495% | -86.622% | 162.791% | -91.654% | - |
News
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3)
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023. Novocure is a global oncology company working to extend survival in some of the most